Relapse recovery: The forgotten variable in multiple sclerosis clinical trials

Area of Science:

• Neurology
• Clinical Trials
• Immunology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Disease-modifying therapies (DMTs) aim to reduce disease activity and slow progression.
• The optimal timing for initiating DMT after an initial relapse remains a key clinical question.

Purpose of the Study:

• To investigate if the timing of DMT initiation (immediate vs. delayed) based on recovery from an initial relapse impacts long-term disability accumulation in MS patients.
• To compare the long-term outcomes of patients with good vs. poor recovery after an initial relapse, stratified by treatment initiation timing.

Main Methods:

• Analysis of a double-blind, placebo-controlled trial of interferon beta-1a in clinically isolated syndrome with a 10-year extension.
• Patients were categorized by recovery status (good vs. not good) and treatment group (immediate vs. 3-year delayed DMT).
• Kaplan-Meier statistics and hazard ratios were used to assess time to disability milestones (Expanded Disability Status Scale [EDSS] ≥2.5 or ≥4.0).

Main Results:

• Patients with poor recovery who received immediate DMT showed a trend towards reduced disability (EDSS ≥2.5) compared to those with delayed treatment.
• Immediate DMT initiation in patients without good recovery was associated with a significantly lower risk of reaching EDSS ≥2.5 at 1 year (HR=0.40, p=0.011).
• Immediate DMT initiation in patients with good recovery also showed a favorable trend in reducing disability accumulation.

Conclusions:

• For MS patients experiencing poor recovery after an initial relapse, immediate DMT initiation is associated with a more favorable, less disabling disease course.
• Early intervention with DMT appears crucial for mitigating long-term disability, particularly in patients who do not achieve full recovery.